Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia

ConclusionsUptake of DAAs has been enthusiastic in the first 18  months of this funding agreement. However, the lack of transparency due to the confidential special pricing agreements means actual government expenditure is unknown. Post-marketing review by the Pharmaceutical Benefits Advisory Committee may enable renegotiation of DAA prices with the sponsors.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research